These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 27068437)

  • 41. Deferred treatment is a safe and viable option for selected patients with mantle cell lymphoma.
    Calzada O; Switchenko JM; Maly JJ; Blum KA; Grover N; Mathews S; Park SI; Gordon M; Danilov A; Epperla N; Fenske TS; Hamadani M; Flowers CR; Cohen JB
    Leuk Lymphoma; 2018 Dec; 59(12):2862-2870. PubMed ID: 29912594
    [TBL] [Abstract][Full Text] [Related]  

  • 42. MicroRNA signature obtained from the comparison of aggressive with indolent non-Hodgkin lymphomas: potential prognostic value in mantle-cell lymphoma.
    Goswami RS; Atenafu EG; Xuan Y; Waldron L; Reis PP; Sun T; Datti A; Xu W; Kuruvilla J; Good DJ; Lai R; Church AJ; Lam WS; Baetz T; Lebrun DP; Sehn LH; Farinha P; Jurisica I; Bailey DJ; Gascoyne RD; Crump M; Kamel-Reid S
    J Clin Oncol; 2013 Aug; 31(23):2903-11. PubMed ID: 23835716
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Expression of SOX11 mRNA in mantle cell lymphoma and its clinical significance].
    Wang YY; Yu Z; Yi SH; Li ZJ; Li CH; Xie ZQ; Li F; Zang MR; Hao M; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2012 Jul; 33(7):556-60. PubMed ID: 22967417
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL).
    Dawar R; Hernandez-Ilizaliturri F
    Best Pract Res Clin Haematol; 2012 Jun; 25(2):185-90. PubMed ID: 22687454
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mantle Cell Lymphoma: First-line Therapy in Patients Not Eligible for Stem Cell Transplantation.
    Nazeef M; Kahl BS
    Curr Treat Options Oncol; 2015 Jun; 16(6):29. PubMed ID: 25975443
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma.
    Andersen NS; Pedersen LB; Laurell A; Elonen E; Kolstad A; Boesen AM; Pedersen LM; Lauritzsen GF; Ekanger R; Nilsson-Ehle H; Nordström M; Fredén S; Jerkeman M; Eriksson M; Väärt J; Malmer B; Geisler CH
    J Clin Oncol; 2009 Sep; 27(26):4365-70. PubMed ID: 19652064
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Common malignancies with uncommon sites of presentation: case 2. Mantle-cell lymphoma of the prostate.
    Chim CS; Loong F; Yau T; Ooi GC; Liang R
    J Clin Oncol; 2003 Dec; 21(23):4456-8. PubMed ID: 14645437
    [No Abstract]   [Full Text] [Related]  

  • 48. Mantle cell lymphoma: clinicopathologic features and treatments.
    Kauh J; Baidas SM; Ozdemirli M; Cheson BD
    Oncology (Williston Park); 2003 Jun; 17(6):879-91, 896; discussion 896-8. PubMed ID: 12846128
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601.
    Till BG; Li H; Bernstein SH; Fisher RI; Burack WR; Rimsza LM; Floyd JD; DaSilva MA; Moore DF; Pozdnyakova O; Smith SM; LeBlanc M; Friedberg JW
    Br J Haematol; 2016 Jan; 172(2):208-18. PubMed ID: 26492567
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment approaches for patients with TP53-mutated mantle cell lymphoma.
    Lew TE; Minson A; Dickinson M; Handunnetti SM; Blombery P; Khot A; Anderson MA; Ritchie D; Tam CS; Seymour JF
    Lancet Haematol; 2023 Feb; 10(2):e142-e154. PubMed ID: 36725119
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group.
    Gressin R; Caulet-Maugendre S; Deconinck E; Tournilhac O; Gyan E; Moles MP; El Yamani A; Cornillon J; Rossi JF; Le Gouill S; Lepeu G; Damaj G; Celigny PS; Maisonneuve H; Corront B; Vilque JP; Casassus P; Lamy T; Colonna M; Colombat P;
    Haematologica; 2010 Aug; 95(8):1350-7. PubMed ID: 20220059
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clonally related composite follicular lymphoma and mantle cell lymphoma with clinicopathologic features and biological implications.
    Wang S; Tzankov A; Xu-Monette ZY; Hoeller S; Wang SA; Richards KL; Zhang S; Said JW; Medeiros LJ; Young KH
    Hum Pathol; 2013 Dec; 44(12):2658-67. PubMed ID: 24071012
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Approach to the Initial Treatment of Older Patients with Mantle Cell Lymphoma.
    Ruan J
    Hematol Oncol Clin North Am; 2020 Oct; 34(5):871-885. PubMed ID: 32861284
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Reproducibility of SOX-11 detection in decalcified bone marrow tissue in mantle cell lymphoma patients.
    Righi S; Pileri S; Agostinelli C; Bacci F; Spagnolo S; Sabattini E
    Hum Pathol; 2017 Jan; 59():94-101. PubMed ID: 27720733
    [TBL] [Abstract][Full Text] [Related]  

  • 55. "Triple hit" SOX11
    Jain P; Tang G; Li S; Wang M
    Am J Hematol; 2021 Jan; 96(1):165-166. PubMed ID: 32356355
    [No Abstract]   [Full Text] [Related]  

  • 56. CD5-undetected by immunohistochemistry, t(11;14)(q13;q32)-positive conjunctival mantle cell lymphoma: a case report.
    Yoo SB; Kim YA; Jeon YK; Kim CW
    Pathol Res Pract; 2008; 204(10):779-83. PubMed ID: 18572329
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.
    Rummel MJ; Niederle N; Maschmeyer G; Banat GA; von Grünhagen U; Losem C; Kofahl-Krause D; Heil G; Welslau M; Balser C; Kaiser U; Weidmann E; Dürk H; Ballo H; Stauch M; Roller F; Barth J; Hoelzer D; Hinke A; Brugger W;
    Lancet; 2013 Apr; 381(9873):1203-10. PubMed ID: 23433739
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial.
    Rummel M; Kaiser U; Balser C; Stauch M; Brugger W; Welslau M; Niederle N; Losem C; Boeck HP; Weidmann E; von Gruenhagen U; Mueller L; Sandherr M; Hahn L; Vereshchagina J; Kauff F; Blau W; Hinke A; Barth J;
    Lancet Oncol; 2016 Jan; 17(1):57-66. PubMed ID: 26655425
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cloned IGH VDJ targets as tools for personalized minimal residual disease monitoring in mature lymphoid malignancies; a feasibility study in mantle cell lymphoma by the Groupe Ouest Est d'Etude des Leucémies et Autres Maladies du Sang.
    Gimenez E; Chauvet M; Rabin L; Puteaud I; Duley S; Hamaidia S; Bruder J; Rolland-Neyret V; Le Gouill S; Tournilhac O; Voog E; Maisonneuve H; Jacob MC; Leroux D; Béné MC; Formisano-Tréziny C; Gabert J; Gressin R; Callanan MB
    Br J Haematol; 2012 Jul; 158(2):186-197. PubMed ID: 22626453
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group.
    Nickenig C; Dreyling M; Hoster E; Pfreundschuh M; Trumper L; Reiser M; Wandt H; Lengfelder E; Unterhalt M; Hiddemann W;
    Cancer; 2006 Sep; 107(5):1014-22. PubMed ID: 16878325
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.